Tags : ProQR

PharmaShots Weekly Snapshot (January 27-31, 2020)

ProQR’s QR-421a Receives FDA’s Rare Pediatric Disease Designation for Retinitis Pigmentosa Published: Jan 30, 2020 | Tags: ProQR, QR-421a, Receives, FDA, Rare Pediatric Disease Designation, Retinitis Pigmentosa 2. Eli Lilly’s Fast-Acting Insulin Lispro Receives CHMP’s Positive Opinion in Patients with Diabetes Published: Jan 31, 2020 | Tags: Eli Lilly, Fast Acting Insulin Lispro, Receives, CHMP, Positive Opinion, […]Read More

PharmaShots Weekly Snapshot (October 14-18, 2019)

1. Johnson & Johnson Initiates Voluntarily Recall of a Single Lot of its Baby Powder in the US Published: Oct 18, 2019 | Tags: JnJ, Initiates, Voluntarily, Recall, Baby Powder, US 2. AbbVie’s Rinvoq (Upadacitinib) Receives CHMP Positive Opinion to Treat Moderate to Severe Active Rheumatoid Arthritis Published: Oct 18, 2019 | Tags: AbbVie, Rinvoq, Upadacitinib, Receives, […]Read More

ProQR Signs Exclusive Worldwide License Agreement with Ionis for IONIS-RHO-2.5

Shots: Ionis Pharmaceuticals will receive an upfront payment in ordinary shares $2.5M, $22.23/share representing 20% premium plus milestones payments and 20% royalties on net sales of QR-1123. ProQR to get WW license rights for Ionis’ IONIS-RHO-2.5 Candidate In 2019, ProQR plans onset of P-I/II trial for QR-1123 in autosomal dominant retinitis pigmentosa (adRP) with awaited […]Read More